Leapfrog Acquisition Corp

Leapfrog Acquisition Corp

Leapfrog Acquisition Corp was incorporated in Delaware in January 2021 by Todd Boehly, a financier who built his career at Guggenheim Partners before founding Eldridge Industries. The vehicle was formed as a special purpose acquisition company, a structure Boehly has used repeatedly to merge private businesses into public markets. Its registration statement with the SEC targeted industries where Boehly already held deep operational and credit expertise, specifically financial services and asset management. The SPAC completed its $200 million initial public offering on the NYSE in March 2021, listing under the ticker LFAC. The prospectus specified a focus on acquiring businesses in the financial services, insurance, and asset management sectors, with a geographic emphasis on North America. A definitive agreement was announced in March 2022 to merge with Boundless Bio, a clinical-stage oncology company, but the transaction was mutually terminated in June 2022 after market conditions shifted. The trust extended its deadline through shareholder votes while searching for an alternative target. Boehly served as Chairman, CEO, and CFO, reflecting the concentrated governance typical of Eldridge-affiliated vehicles. His parallel entities provide a wide operational infrastructure: Eldridge owns stakes in asset manager Security Benefit, insurer Clear Spring, and the Los Angeles Dodgers, among dozens of other holdings. John Hu, a senior partner at Eldridge, and Amy Boehly Wolfe, a vice president at Eldridge, rounded out the board. As of the SPAC’s mid-2023 liquidation filing, the trust held approximately $46 million after redemptions. The SPAC's structural differentiator is its embedded relationship with Eldridge's credit and insurance platform. Unlike standalone sponsor vehicles that rely solely on deal-by-deal PIPE financing, Leapfrog could in theory tap Eldridge's permanent capital base and LP relationships from Security Benefit's general account to backstop transactions — a sourcing advantage that independent SPACs cannot replicate.